Third-generation MMP inhibitors: Recent advances in the development of highly selective inhibitors

The Cancer Degradome: Proteases and Cancer Biology

Volumn , Issue , 2008, Pages 811-825

  Yiotakis, Athanasios ^a   Dive, Vincent ^b  

^a UNIVERSITY OF ATHENS   (Greece)

^b SERVICE DE CHIMIE BIOORGANIQUE ET DE MARQUAGE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84900154002     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/978-0-387-69057-5_38     Document Type: Chapter

References (44)

1. Amour A, Slocombe P M, Webster A et al. (1998) TNF-alpha converting enzyme (TACE) is inhibited by TIMP-3. FEBS Letters 435: 39-44.
2. Babine R E, Bender S L (1997) Molecular recognition of proteinminus signLigand complexes: applications to drug design. Chemical Reviews 97: 1359-1472.
3. Bertini I, Calderone V, Cosenza M et al. (2005) Conformational variability of matrix metalloproteinases: beyond a single 3D structure. Proceedings of the National Academy of Sciences of the United States of America 102: 5334-5339.
4. Bertini I, Calderone V, Fragai M et al. (2006) Snapshots of the reaction mechanism of matrix metalloproteinases. Angewandte Chemie (International Edition in English) 45: 7952-7955.
5. Bertini I, Calderone V, Fragai M et al. (2007) Exploring the subtleties of drug-receptor interactions: the case of matrix metalloproteinases. Journal of the American Chemical Society 129: 2466-2475.
6. Bode W, Maskos K (2003) Structural basis of the matrix metalloproteinases and their physiological inhibitors, the tissue inhibitors of metalloproteinases. Biological Chemistry 384: 863-872.
7. Brown S, Meroueh S O, Fridman R et al. (2004) Quest for selectivity in inhibition of matrix metalloproteinases. Current Topics in Medicinal Chemistry 4: 1227-1238.
8. Chen J M, Nelson F C, Levin J I et al. (2000) Structure-based design of a novel, potent and selective inhibitor for MMP-13 utilizing NMR spectroscopy and computer-aided molecular design. Journal of the American Chemical Society 122: 9648-9654.
9. Cheng F, Zhang R, Luo X et al. (2002) Quantum chemistry study on the interaction of the exogenous ligands and the catalytic zinc ion in matrix metalloproteinases. The Journal of Physical Chemistry B 106: 4552-4559.
10. Clark I M, Cawston T E (1989) Fragments of human fibroblast collagenase. Purification and characterization. The Biochemical Journal 263: 201-206.
11. Corradi H R, Chitapi I, Sewell B T et al. (2007) The structure of testis angiotensin-converting enzyme in complex with the C domain-specific inhibitor RXPA380. Biochemistry 46: 5473-5478.
12. Coussens LM, Fingleton B, Matrisian LM(2002) Matrix metalloproteinase inhibitors and cancer: trials and tribulations. Science (New York, NY) 295: 2387-2392.
13. Cuniasse P, Devel L, Makaritis A et al. (2005) Future challenges facing the development of specific active-site-directed synthetic inhibitors of MMPs. Biochimie 87: 393-402.
14. Devel L, Rogakos V, David A et al. (2006) Development of selective inhibitors and substrate of matrix metalloproteinase-12. The Journal of Biological Chemistry 281: 11152-11160.
15. Dive V, Georgiadis D, Matziari M et al. (2004) Phosphinic peptides as zinc metalloproteinase inhibitors. Cellular and Molecular Life Sciences 61: 2010-2019.
16. Egeblad M, Werb Z (2002) New functions for the matrix metalloproteinases in cancer progression. Nature Reviews 2: 161-174.
17. Engel C K, Pirard B, Schimanski S et al. (2005) Structural basis for the highly selective inhibition of MMP-13. Chemistry &Biology 12: 181-189.
18. Fingleton B (2007) Matrix metalloproteinases as valid clinical targets. Current Pharmaceutical Design 13: 333-346.
19. Gall A L, Ruff M, Kannan R et al. (2001) Crystal structure of the stromelysin-3 (MMP-11) catalytic domain complexed with a phosphinic inhibitor mimicking the transition-state. Journal of Molecular Biology 307: 577-586.
20. Grams F, Dive V, Yiotakis A et al. (1996) Structure of astacin with a transition-state analogue inhibitor. Nature Structural Biology 3: 671-675.
21. Hajduk P J, Sheppard G, Nettesheim D G et al. (1997) Discovery of potent nonpeptide inhibitors of stromelysin using SAR by NMR. Journal of the American Chemical Society 119: 5818-5827.
22. Johnson A R, Pavlovsky A G, Ortwine D F et al. (2007) Discovery and characterization of a novel inhibitor of matrix metalloprotease-13 (MMP13) that reduces cartilage damage in vivo without joint fibroplasia side effects. The Journal of Biological Chemistry 282: 27781-27791.
23. Li Y C, Zhang X, Melton R et al. (1998) Solution structure of the catalytic domain of human stromelysin-1 complexed to a potent, nonpeptidic inhibitor. Biochemistry 37: 14048-14056.
24. Maskos K, Fernandez-Catalan C, Huber R et al. (1998) Crystal structure of the catalytic domain of human tumor necrosis factor-alpha-converting enzyme. Proceedings of the National Academy of Sciences of the United States of America 95: 3408-3412.
25. Matter H, Schudok M (2004) Recent advances in the design of matrix metalloprotease inhibitors. Current Opinion in Drug Discovery &Development 7: 513-535.
26. Morales R, Perrier S, Florent J M et al. (2004) Crystal structures of novel non-peptidic, non-zinc chelating inhibitors bound to MMP-12. Journal of Molecular Biology 341: 1063-1076.
27. Moy F J, Chanda P K, Chen J et al. (2002) Impact of mobility on structure-based drug design for the MMPs. Journal of the American Chemical Society 124: 12658-12659.
28. Nar H, Werle K, Bauer M M et al. (2001) Crystal structure of human macrophage elastase (MMP- 12) in complex with a hydroxamic acid inhibitor. Journal of Molecular Biology 312: 743-751.
29. Netzel-Arnett S, Sang Q X, MooreWG et al. (1993) Comparative sequence specificities of human 72- and 92-kDa gelatinases (type IV collagenases) and PUMP (matrilysin). Biochemistry 32: 6427-6432.
30. Overall C M, Kleifeld O (2006) Towards third generation matrix metalloproteinase inhibitors for cancer therapy. British Journal of Cancer 94: 941-946.
31. Parker M H, Lunney E A, Ortwine D F et al. (1999) Analysis of the binding of hydroxamic acid and carboxylic acid inhibitors to the stromelysin-1 (matrix metalloproteinase-3) catalytic domain by isothermal titration calorimetry. Biochemistry 38: 13592-13601.
32. Parker M H, Ortwine D F, OBrien P M et al. (2000) Stereoselective binding of an enantiomeric pair of stromelysin-1 inhibitors caused by conformational entropy factors. Bioorganic &Medicinal Chemistry Letters 10: 2427-2430.
33. Peng S X, StrojnowskiMJ, Hu J K et al. (1999) Gas chromatographic-mass spectrometric analysis of hydroxylamine for monitoring the metabolic hydrolysis of metalloprotease inhibitors in rat and human liver microsomes. Journal of Chromatography 724: 181-187.
34. Puerta D T, Lewis J A, Cohen SM(2004) New beginnings for matrix metalloproteinase inhibitors: identification of high-affinity zinc-binding groups. Journal of the American Chemical Society 126: 8388-8389.
35. Puerta D T, Mongan J, Tran B L et al. (2005) Potent, selective pyrone-based inhibitors of stromelysin-1. Journal of the American Chemical Society 127: 14148-14149.
36. Saghatelian A, Jessani N, Joseph A et al. (2004) Activity-based probes for the proteomic profiling of metalloproteases. Proceedings of the National Academy of Sciences of the United States of America 101: 10000-10005.
37. Seltzer J L, Akers K T, Weingarten H et al. (1990) Cleavage specificity of human skin type IV collagenase (gelatinase). Identification of cleavage sites in type I gelatin, with confirmation using synthetic peptides. The Journal of Biological Chemistry 265: 20409-20413.
38. Skiles J W, Gonnella N C, Jeng A Y (2004) The design, structure, and clinical update of small molecular weight matrix metalloproteinase inhibitors. Current Medicinal Chemistry 11: 2911-2977.
39. Stack M S, Gray R D (1989) Comparison of vertebrate collagenase and gelatinase using a new fluorogenic substrate peptide. The Journal of Biological Chemistry 264: 4277-4281.
40. Tochowicz A, Maskos K, Huber R et al. (2007) Crystal structures of MMP-9 complexes with five inhibitors: contribution of the flexible Arg424 side-chain to selectivity. Journal of Molecular Biology 371: 989-1006.
41. Turk B E, Huang L L, Piro E T et al (2001) Determination of protease cleavage site motifs using mixture-based oriented peptide libraries. Nature Biotechnology 19: 661-667.
42. Visse R, Nagase H (2003) Matrix metalloproteinases and tissue inhibitors of metalloproteinases: structure, function, and biochemistry. Circulation Research 92: 827-839.
43. Whittaker M, Floyd C D, Brown P, Gearing A J (1999) Design and therapeutic application of matrix metalloproteinase inhibitors. Chemical Reviews 99: 2735-2776.
44. Yan Y L, Cohen S M (2007) Efficient synthesis of 5-amido-3-hydroxy-4- pyrones as inhibitors of matrix metalloproteinases. Organic Letters 9: 2517-2520